Brought to you by 
Trevena nets $60.2mm through its IPO
19 Feb 2015
Executive Summary
Trevena Inc. (GPCR therapeutics for cardiovascular and neurological conditions) netted $60.2mm through the initial public offering of 9.25mm common shares at $7. Existing shareholders, including partner Forest Laboratories Inc., purchased an aggregate 2.1mm shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trevena nets $60.2mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice